Vanda ’s latest study failed. But revenue grew in 2019.

The D.C. biotech ’s phase 3 clinical trial of a drug candidate failed to reduce symptoms among adult patients with an itchy skin condition called atopic dermatitis.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news